Amarin Appoints Michael W. Kalb Chief Financial Officer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amarin Appoints Michael W. Kalb Chief Financial Officer

BEDMINSTER, NJ and DUBLIN, IRELAND --(Marketwired - June 30, 2016) - Amarin Corporation plc ( NASDAQ : AMRN ) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr. Kalb brings over 20 years of international financial operations and accounting advisory experience.

"We are delighted to welcome Mike to our team and look forward to leveraging his extensive experience and leadership capabilities as we continue to grow our commercial business and work toward the completion of our cardiovascular outcomes study," commented John F. Thero, president and chief executive officer of Amarin. "Mike's broad, global business and pharmaceutical experience will further strengthen our executive, financial and operational capabilities as we continue our commercial growth and work toward expanding our business in the future."

Mr. Kalb joins Amarin from Taro Pharmaceutical Industries, Ltd., a publicly-traded, multinational, science-based pharmaceutical company where he served as chief financial officer and chief accounting officer. Prior to joining Taro, Mr. Kalb was a director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. Mr. Kalb's experience also includes over ten years at Ernst & Young, LLP within its Transaction Advisory Services Group and Audit and Assurance Services Group. He is a certified public accountant.

Mr. Kalb added, "I am very happy to become a part of the Amarin team. The company has made great progress recently in increasing awareness of Vascepa ® and its clinical profile. I am excited both by Vascepa's revenue growth and its large potential upside and look forward to working with the Amarin team to help build upon the company's success and drive shareholder value."

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa ® (icosapent ethyl), Amarin's first FDA-approved product, is a highly pure omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com . For more information about Amarin, visit www.amarincorp.com .

Forward-looking statements

This press release contains forward-looking statements, including statements about Amarin's commercial development and research programs and the anticipated contribution of executives to Amarin's progress. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively commercialize Vascepa will depend in part on its ability to continue to effectively finance its development programs, create market demand for Vascepa through education, marketing and sales activities, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: individual contributions to Amarin from the named executives, uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that related cost may increase beyond expectations; the risk that Vascepa may not show clinically meaningful effects in REDUCE-IT or support regulatory approvals for cardiovascular risk reduction; and the risk that Amarin's patent applications and patents may not be sufficient to protect the company from generic competition. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Availability of Other Information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website ( www.amarincorp.com ), our investor relations website ( http://www.amarincorp.com/investor-splash.html ), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information: Investor Relations: Kathryn McNeil Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com Lee M. Stern Trout Group In U.S.: +1 (646) 378-2992 lstern@troutgroup.com Media Inquiries: Kristie Kuhl Finn Partners In U.S.: +1 (212) 583-2791 Kristie.kuhl@finnpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 121

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 0

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into Inspire Medical Systems: What Investors Need to Know

Updated Category News Views 166

Investigation of Inspire Medical Systems and Shareholder Rights Faruqi & Faruqi, LLP, a prominent player in the field of securities law, is taking proactive steps to investigate potential claims regarding Inspire Medical Systems, Inc. This company has garnered attention recently due to its significant developments and ongoing operations. Investors who have experienced...

Continue Reading
Ecopro BM Faces Downgrade Amidst Battery Industry Challenges

Updated Category News Views 71

Market Response to Ecopro BM's Stock Downgrade Recently, Ecopro BM Co Ltd (247540:KS) faced a significant shift in its market perception as Nomura/Instinet downgraded the company's stock rating from Buy to Neutral. This adjustment comes with a newly revised price target focused on KRW240,000, a notable decrease from the previous KRW290,000. The decision is primarily...

Continue Reading
Exploring the Current State of Sea's Options Trading Landscape

Updated Category News Views 163

Exploring the Current State of Sea's Options Trading Landscape Recent market movements surrounding Sea (NYSE: SE) have sparked considerable interest among investors and traders alike. A comprehensive analysis of the options trading history for Sea reveals notable bearish activity. In our investigation, we identified 16 unusual trades that reflect a cautious outlook among...

Continue Reading
Empowering Women in Whiskey: The Rise of Lythgoe Bourbon

Updated Category News Views 94

Celebrating Women in the Whiskey Industry with Lythgoe Bourbon In a male-dominated field, one entrepreneur is making waves by honoring women in whiskey. The story of Lythgoe Bourbon begins with Dina Coker, who recognized a remarkable trend in the bourbon market. Despite the traditional narrative focused on male brands and locations in Kentucky, women are a significant...

Continue Reading
Waste Connections Declares Quarterly Cash Dividend for Investors

Updated Category News Views 110

Waste Connections Announces Regular Quarterly Cash Dividend Waste Connections, Inc. (TSX/NYSE: WCN) is making strides in providing returns for its shareholders by declaring a regular quarterly cash dividend of $0.315 U.S. per common share. This decision was made by the Company's Board of Directors and reflects their commitment to offering consistent shareholder value. The...

Continue Reading